Top Glove Corporation Bhd.

OTCPK:TPGV.F Stock Report

Market Cap: US$2.0b

Top Glove Corporation Bhd Valuation

Is TPGV.F undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TPGV.F when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: TPGV.F ($0.21) is trading below our estimate of fair value ($0.25)

Significantly Below Fair Value: TPGV.F is trading below fair value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TPGV.F?

Key metric: As TPGV.F is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for TPGV.F. This is calculated by dividing TPGV.F's market cap by their current revenue.
What is TPGV.F's PS Ratio?
PS Ratio3.5x
SalesRM 2.52b
Market CapRM 8.81b

Price to Sales Ratio vs Peers

How does TPGV.F's PS Ratio compare to its peers?

The above table shows the PS ratio for TPGV.F vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average4.1x
XRAY DENTSPLY SIRONA
0.9x1.2%US$3.4b
ESTA Establishment Labs Holdings
6.9x24.2%US$1.1b
STAA STAAR Surgical
3.9x13.7%US$1.4b
VIVO Meridian Bioscience
4.5xn/aUS$1.5b
TPGV.F Top Glove Corporation Bhd
3.5x23.1%US$8.8b

Price-To-Sales vs Peers: TPGV.F is good value based on its Price-To-Sales Ratio (3.5x) compared to the peer average (4.1x).

Price to Sales Ratio vs Industry

How does TPGV.F's PS Ratio compare vs other companies in the US Medical Equipment Industry?

52 CompaniesPrice / SalesEstimated GrowthMarket Cap
VREX Varex Imaging
0.7x2.0%US$568.78m
ARAY Accuray
0.4x5.4%US$182.02m
NVRO Nevro
0.4x2.5%US$166.75m
KEQU Kewaunee Scientific
0.5xn/aUS$109.99m
TPGV.F 3.5xIndustry Avg. 3.3xNo. of Companies52PS02.85.68.411.214+
52 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: TPGV.F is expensive based on its Price-To-Sales Ratio (3.5x) compared to the US Medical Equipment industry average (3.3x).

Price to Sales Ratio vs Fair Ratio

What is TPGV.F's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TPGV.F PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio3.5x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate TPGV.F's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TPGV.F forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$0.21
US$0.25
+18.9%
16.6%US$0.32US$0.16n/a19
Nov ’25US$0.20
US$0.25
+21.1%
16.6%US$0.32US$0.16n/a19
Oct ’25n/a
US$0.26
0%
18.6%US$0.35US$0.17n/a19
Sep ’25US$0.17
US$0.24
+38.2%
20.7%US$0.33US$0.16n/a19
Aug ’25US$0.21
US$0.22
+3.7%
21.9%US$0.31US$0.14n/a20
Jul ’25US$0.23
US$0.21
-5.5%
20.9%US$0.30US$0.13n/a20
Jun ’25US$0.22
US$0.18
-16.8%
23.0%US$0.26US$0.11n/a20
May ’25n/a
US$0.17
0%
18.3%US$0.23US$0.11n/a20
Apr ’25US$0.13
US$0.17
+31.2%
18.3%US$0.23US$0.11n/a20
Mar ’25US$0.14
US$0.17
+14.9%
19.0%US$0.23US$0.10n/a20
Feb ’25US$0.16
US$0.16
+4.8%
17.4%US$0.21US$0.11n/a20
Jan ’25US$0.19
US$0.17
-12.0%
17.4%US$0.22US$0.11n/a20
Dec ’24US$0.23
US$0.14
-35.8%
19.0%US$0.21US$0.10n/a19
Nov ’24n/a
US$0.14
0%
19.0%US$0.21US$0.10US$0.2019
Oct ’24US$0.13
US$0.16
+28.1%
27.3%US$0.29US$0.096n/a20
Sep ’24n/a
US$0.16
0%
27.3%US$0.29US$0.097US$0.1721
Aug ’24US$0.19
US$0.16
-16.1%
27.3%US$0.29US$0.096US$0.2121
Jul ’24n/a
US$0.16
0%
27.3%US$0.29US$0.096US$0.2321
Jun ’24US$0.25
US$0.16
-37.8%
31.4%US$0.30US$0.10US$0.2221
May ’24n/a
US$0.16
0%
27.1%US$0.24US$0.10n/a21
Apr ’24US$0.18
US$0.16
-13.9%
26.7%US$0.24US$0.10US$0.1321
Mar ’24n/a
US$0.13
0%
26.8%US$0.24US$0.074US$0.1421
Feb ’24US$0.16
US$0.14
-9.3%
48.1%US$0.43US$0.075US$0.1621
Jan ’24US$0.18
US$0.14
-23.4%
48.2%US$0.41US$0.072US$0.1921
Dec ’23US$0.16
US$0.14
-10.9%
43.6%US$0.41US$0.10US$0.2321
Nov ’23n/a
US$0.14
0%
43.3%US$0.39US$0.097n/a21

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Elevance Health

US$95.3b

Operates as a health benefits company in the United States.

ELV

US$407.04

7D

-5.2%

1Y

-12.2%

Lantheus Holdings

US$5.5b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$80.84

7D

-8.5%

1Y

18.6%

Enhabit

US$382.7m

Provides home health and hospice services in the United States.

EHAB

US$7.44

7D

-6.1%

1Y

-23.2%